AUS
NZ
UK
CA
USA
IND
WAM Global Limited has issued its June 2026 investment update, spotlighting substantial gains driven by its stakes in ASML Holding and Edwards Lifesciences Corporation. The firm experienced portfolio growth propelled by strategic investments in the semiconductor and medical technology industries, reinforcing WAM Global's commitment to undervalued growth companies with strong future catalysts.
Key Points
- WAM Global Limited (ASX:WGB)
- Investment portfolio expanded in June 2026
- ASML Holding and Edwards Lifesciences were major contributors
- Investors advised to monitor forthcoming CMS decision impacting Edwards
WAM Global's Investment Portfolio Expands in June 2026
WAM Global Limited, renowned for targeting undervalued growth prospects, announced an increase in its investment portfolio for June 2026. The company specializes in identifying international growth firms with catalysts likely to trigger share price re-ratings. This approach continues to yield positive results, as reflected in the portfolio's performance.
The company reported a net tangible asset (NTA) value of $804.9 million. Since its inception in June 2018, the portfolio has delivered an annualised return of 8.2%, compared to the MSCI World Index (AUD) return of 13.4%. The month-end share price stood at $2.11, underscoring the company's solid market standing.
ASML Holding's Impact on Portfolio Performance
ASML Holding, a pivotal investment for WAM Global, played a significant role in the portfolio's June gains. ASML leads the semiconductor equipment manufacturing industry, holding a monopoly in extreme ultraviolet lithography technology essential for semiconductor fabrication. This positions ASML to benefit from increased capital expenditures linked to artificial intelligence advancements.
Recent events, including Micron Technology's strong quarterly earnings and SpaceX's successful IPO, have enhanced ASML's outlook. These developments indicate sustained demand for ASML's lithography systems, potentially driving strong earnings growth. ASML's strategic collaborations with industry leaders like Taiwan Semiconductor Manufacturing Company, Intel, and Samsung Electronics further bolster its growth potential.
Edwards Lifesciences' Strategic Role in Medical Technology
Edwards Lifesciences Corporation, another key holding for WAM Global, also contributed notably to portfolio gains. Edwards is a global frontrunner in minimally invasive heart valve and structural heart treatments. Its Transcatheter Aortic Valve Replacement (TAVR) franchise, which generated over 70% of revenues in 2025, remains a primary growth engine.
The company's shares outperformed in June following a US Centers for Medicare and Medicaid Services (CMS) proposal to broaden reimbursement criteria for TAVR procedures. If approved, this would expand patient access to Edwards' TAVR products, improve outcomes, and enlarge the market. Investors await the final CMS decision expected by September 2026, which could further strengthen Edwards' market position.
Dividend Performance and Financial Overview
WAM Global sustains a robust dividend policy, offering an annualised fully franked interim dividend yield of 6.3%. The grossed-up dividend yield is 9.0%, reflecting the company's dedication to delivering shareholder value. Since inception, dividends paid total 77.1 cents per share, including franking credits amounting to 110.1 cents per share.
The net current and deferred tax asset/liability position for June 2026 is 5.51 cents per share. This encompasses tax assets from investment company acquisitions and income tax losses available for future use, indicating effective tax management supporting shareholder returns.
Diversification Across Sectors and Regions
WAM Global's portfolio is diversified across multiple sectors and geographies. Industrials represent the largest sector exposure at 30.5%, followed by information technology at 15.5%. Consumer discretionary and capital markets also hold significant shares.
Geographically, the United States accounts for 65.3% of the portfolio, reflecting a focus on high-growth markets. Other notable exposures include Germany, France, and Australia. This diversification strategy mitigates risk while capitalizing on global growth opportunities.
Risks and Growth Potential in Semiconductor and Medical Sectors
While investments in ASML and Edwards Lifesciences offer substantial growth potential, they carry inherent risks. The semiconductor sector faces intense competition and rapid technological evolution. ASML's continued success depends on maintaining its technological leadership and securing key partnerships.
In the medical field, Edwards encounters regulatory and competitive challenges. The CMS proposal's outcome is critical for its growth trajectory. Additionally, ongoing innovation and product expansion are vital to sustaining market leadership. Investors should closely monitor these factors as they may impact WAM Global's portfolio performance.
Future Outlook: Strategic Priorities and Market Trends
WAM Global's emphasis on undervalued growth companies with identifiable catalysts positions it favorably for future achievements. Its investment process focuses on uncovering mispriced opportunities and leveraging catalysts to generate value, a strategy that has delivered strong returns and is expected to persist.
As the global economy evolves, WAM Global remains committed to adjusting its portfolio to seize emerging opportunities. Concentrating on sectors like technology and healthcare, which are expected to grow, aligns with prevailing market trends. Investors should stay informed on updates regarding key investments and strategic adjustments that may influence the company's performance.
